Effect of diabetes mellitus and glycemic control on the prognosis of invasive bladder cancer: DM and Glycemic Control on the Prognosis of Bladder Cancer

Muhammad Haroon  Ghous; Muhammad  Hafeez; Sikander  Afzal; Shahid Mahmud  Malik; Mahwish  Arooj; Hafiza Sobia  Ramzan

doi:10.54393/pbmj.v5i1.263

Authors

Muhammad Haroon Ghous Department of Urology, University College of Medicine, University of Lahore
Muhammad Hafeez Department of Oncology, University College of Medicine, University of Lahore
Sikander Afzal Department of Surgery, University College of Medicine, University of Lahore
Shahid Mahmud Malik Health Sciences, University College of Medicine, University of Lahore
Mahwish Arooj University College of Medicine, University of Lahore
Hafiza Sobia Ramzan University of Lahore

DOI:

https://doi.org/10.54393/pbmj.v5i1.263

Keywords:

Glycemic, Patients, Diabetes melletus

Abstract

A patient's prognosis for cancer treatment is thought to be affected by their presence of diabetes mellitus (DM). Epidemiological studies show that type 2 diabetes raises the risk of a wide range of cancers, including colorectal, breast, endometrial, and hepatocellular carcinoma. Findings for bladder cancer were hard to comprehend and thus no proof has been presented. Objectives: Invasive bladder cancer prognosis will be examined in this study in relation to diabetes and glycemic control. Methodology of the study: Researcher performed this cross-sectional study between January 2011 and January 2021 at Galway Hospital, Ireland and University Lahore Teaching Hospital in Lahore, Pakistan. The data was collected from 136 bladder cancer patients during the period of these five years. The data was collected with the permission of ethical committee of hospitals. Patients with last two years of DM were include in this study. Results: The study was completed by 136 patients. Their mean age was 53.2 ± 8.4 years (range: 36-61 years). There were more males than females (60% vs. 40%). Table 1 provides an overview of their clinical and demographic data. Conclusion: Diabetes mellitus is a metabolic condition that affects all main bodily systems, although it is not linked to the advancement of bladder cancer, according to the findings. However, poor glycemic management is linked to a greater recurrence rate. In patients with DM and invasive bladder cancer, glycemic management should be one of the therapy aims.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

Ahn JH, Jung SI, Yim SU, Kim SW, Hwang EC, Kwon DD. Impact of glycemic control and metformin use on the recurrence and progression of non-muscle invasive bladder Cancer in patients with diabetes mellitus. J Korean Med Sci. 2016;31(9):1464–71. https://doi.org/10.3346/jkms.2016.31.9.1464.

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85. https://doi.org/10.2337/dc10-0666.

Chen Y, Wu F, Saito E, Lin Y, Song M, Luu HN, et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia cohort consortium. Diabetologia. 2017;60(6):1022–32. https://doi.org/10.1007/s00125-017-4229-z.

Tai YS, Chen CH, Huang CY, Tai HC, Wang SM, Pu YS. Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. Diabetes Metab Res Rev. 2015;31(3):307–14. https://doi.org/10.1002/dmrr.2614.

Huang, WL., Huang, KH., Huang, CY. et al. Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study. BMC Urol 20, 117 (2020). https://doi.org/10.1186/s12894-020-00684-5

Ahn JH, Jung SI, Yim SU, Kim SW, Hwang EC, Kwon DD. Impact of Glycemic Control and Metformin Use on the Recurrence and Progression of Non-Muscle Invasive Bladder Cancer in Patients with Diabetes Mellitus. J Korean Med Sci. 2016 Sep;31(9):1464-1471. https://doi.org/10.3346/jkms.2016.31.9.1464

Tai YS, Chen CH, Huang CY, Tai HC, Wang SM, Pu YS. Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. Diabetes Metab Res Rev 2015; 31: 307-14.

Aldousari S, Kassouf W. Update on the Management of Non-Muscle Invasive Bladder Cancer. Can Urol Assoc J J Assoc Urol Can (2010) 4:56–64. doi: 10.5489/cuaj.777

Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic Aspects of Bladder Cancer: What Are the Benefits and Costs? World J Urol (2009) 27:295–300. doi: 10.1007/s00345-009-0395-z

Zhang G, Steinbach D, Grimm M-O, Horstmann M. Utility of the EORTC Risk Tables and CUETO Scoring Model for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients Treated With Routine Second Transurethral Resection. World J Urol (2019) 37:2699–705. doi: 10.1007/s00345-019-02681-2

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results From the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Res Clin Pract (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843

Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, et al. Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Exp Diabetes Res (2012) 2012:789174. doi: 10.1155/2012/789174

Ferro M, Katalin MO, Buonerba C, Marian R, Cantiello F, Musi G, et al. Type 2 Diabetes Mellitus Predicts Worse Outcomes in Patients With High-Grade T1 Bladder Cancer Receiving Bacillus Calmette-Guérin After Transurethral Resection of the Bladder Tumor. Urol Oncol (2020) 38:459–64. doi: 10.1016/j.urolonc.2020.02.016

Evers J, Grotenhuis AJ, Aben KKH, Kiemeney LALM, Vrieling A. No Clear Associations of Adult BMI and Diabetes Mellitus With Non-Muscle Invasive Bladder Cancer Recurrence and Progression. PloS One (2020) 15:e0229384. doi: 10.1371/journal.pone.0229384

Hu, Jiao MDa; Chen, Jin-bo MDa; Cui, Yu MD, PhDa; Zhu, Ye-wen MDa; Ren, Wen-biao MDa; Zhou, Xu MD, PhDa,b; Liu, Long-fei MD, PhDa; Chen, He-qun MDa; Zu, Xiong-bing MD, PhDa,* Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients, Medicine: July 2018 - Volume 97 - Issue 30 - p e11596 doi: 10.1097/MD.0000000000011596

Ma F, Liu ZB, Qu L, Hao S, Liu G, Wu J, Shao Z. Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People’s Republic of China. Onco Targets Ther. 2014;7:2147-2154

https://doi.org/10.2147/OTT.S71095

Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121(11):2381–6. https://doi.org/10.1002/ijc.23192.

Gonzalez-Roibon N, Kim JJ, Faraj SF, Chaux A, Bezerra SM, Munari E, et al. Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy. Urology. 2014;83(6):1444 e1–6. https://doi.org/10.1016/j.urology.2014.01.028.

Gill, E.; Sandhu, G.; Ward, D.G.; Perks, C.M.; Bryan, R.T. The Sirenic Links between Diabetes, Obesity, and Bladder Cancer. Int. J. Mol. Sci. 2021, 22, 11150. https:// doi.org/10.3390/ijms222011150